产品名称
Anti-MLL/HRX Antibody, NT., clone N4.4, clone N4.4, Upstate®, from mouse
technique(s)
immunoprecipitation (IP): suitable
western blot: suitable
biological source
mouse
conjugate
unconjugated
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
N4.4, monoclonal
species reactivity
mouse, human
manufacturer/tradename
Upstate®
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... KMT2A(4297)
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Physical form
Format: Purified
Immunoaffinity Purified immunoglobulin in 0.014M phosphate buffer, pH 7.6, 0.175M NaCl, 0.07% sodium azide, and 30% glycerol.
General description
300 kDa
The acute lymphoblastic leukaemia (ALL)-1 (also known as MLL, HRX, HTRX, and TRX1) gene on human chromosome 11q23 is the site of many locally clustered chromosomal alterations associated with several types of acute leukaemias, including deletions, partial duplications and translocations. Structurally variant proteins derived from the altered gene presumably cause the malignant transformation of early haemopoietic progenitor cells.
Immunogen
MBP fusion protein corresponding to residues 161-356 of human mixed lineage leukemia, MLL
Analysis Note
routinely evaluated by immunoblot on nuclear extract from K562 cells
Application
Detect MLL/HRX with Anti-MLL/HRX Antibody, N-term., clone N4.4 (Mouse Monoclonal Antibody), that has been shown to work in IP & WB.
Biochem/physiol Actions
Recognizes N-terminal proteolytic fragment of MLL (MLLN).
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
Anmaar M Abdul-Nabi et al.
PloS one, 5(8), e12464-e12464 (2010-09-02)
Different fusion oncogenes in acute myeloid leukemia (AML) have distinct clinical and laboratory features suggesting different modes of malignant transformation. Here we compare the in vitro effects of representatives of 4 major groups of AML fusion oncogenes on primary human
Chi Wai So et al.
Molecular and cellular biology, 22(18), 6542-6552 (2002-08-23)
MLL-AFX is a fusion gene created by t(X;11) chromosomal translocations in a subset of acute leukemias of either myeloid or lymphoid derivation. It codes for a chimeric protein consisting of MLL fused to AFX, a forkhead transcription factor that normally
Clara Bueno et al.
Cell research, 22(6), 986-1002 (2012-01-04)
The MLL-AF4 fusion gene is a hallmark genomic aberration in high-risk acute lymphoblastic leukemia in infants. Although it is well established that MLL-AF4 arises prenatally during human development, its effects on hematopoietic development in utero remain unexplored. We have created
Inducible MLL-AF9 Expression Drives an AML Program during Human Pluripotent Stem Cell-Derived Hematopoietic Differentiation.
Heuts, et al.
Cells, 12 (2023)
Matthew J Smith et al.
Nature communications, 8(1), 1099-1099 (2017-10-25)
Elucidation of activation mechanisms governing protein fusions is essential for therapeutic development. MLL undergoes rearrangement with numerous partners, including a recurrent translocation fusing the epigenetic regulator to a cytoplasmic RAS effector, AF6/afadin. We show here that AF6 employs a non-canonical
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持